ENDOTHELIAL PROGENITOR CELLS IN MYELOPROLIFERATIVE NEOPLASMS – PRELIMINARY REPORT
DOI:
https://doi.org/10.12775/MBS.2014.011Keywords
endothelial progenitor cells, myeloproliferative neoplasmsAbstract
The aim of this study was to assess the number of endothelial progenitor cells in patients with chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET). The study involved 21 patients (mean age 61.77) with myeloproliferative neoplasms, hospitalized and diagnosed at the Hematology Clinic of Dr. J. Biziel University Hospital No. 2 in Bydgoszcz, Poland. M a t e r i a l a n d m e t h o d s . The study group included 12 patients with ET, 5 with PV, 4 with CML. The control group consisted of 25 healthy volunteers, age- and sex- matched. The material for the study was venous blood collected from the elbow vein into tube containing K2EDTA. The number of endothelial progenitor cells was measured with FACSCalibur flow cytometer (Becton Dickinson, San Diego, USA) using monoclonal antibodies directed against antigens specific for endothelial progenitor cells (EPCs). R e s u l t s . We observed significantly increased number of EPCs in patients with myeloproliferative neoplasms (MPNs) in comparison to the control group. Detailed analysis showed slightly higher number of EPCs in patients with PV and ET than in the controls, but the differences were not statistically significant. The highest statistically significant number of EPCs was observed in patients with CML. C o n c l u s i o n s . Increased number of EPCs in patients with myeloproliferative neoplasms may indicate increased angiogenesis in these diseases and participation of EPCs in the process of neovascularization.
References
Prochorec-Sobieszek M. Nowotwory mielodysplastyczne/mieloproliferacyjne - nowości i problemy diagnostyczne. Hematologia 2010; 1 (3): 185-194.
Szumowska A., Galar M., Kłoczko J. Haemostasis disturbances in polycythemia vera and essential thrombocythemia. Acta Haematol Pol 2012; 43 (2b): 187-191.
Vainchenker W., Delhommeau F., Constantinescu SN. et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118 (7): 1723-1735.
Tefferi A., Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 2006; 19 (3): 365-385. DOI:
Hellmann A. Rozpoznawanie i możliwości leczenia zespołów mieloproliferacyjnych. Pol Arch Med Wewn 2008; 118 (12): 756-760.
Hrycek E., Wojakowski W. The influence of the biological age on function of endothelial progenitor cells. Kardiol Pol 2010; 68 (suppl. 5): 405-411.
Góra - Tybor J., Krawczyńska A. Circulating endothelial cells - a noninvasive angiogenesis marker. Acta Haematol Pol 2007; 38 (2): 195-202.
Partyka Ł., Siwiec K., Niżankowski R., et al. Endothelial progenitor cells (EPCs) in therapy. Acta Angiol 2003; 9 (2): 53-62.
Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85 (3): 221-228.
Wróbel T. Angiogenesis in haematologic malignancies. Acta Haematol Pol 2004; 35 (4): 493-504.
Krawczyk A., Izdebska M., Grzanka A. The influence of hyperglycemia on functions of endothelial progenitor cells. Pol Merkuriusz Lek 2009; 26 (153): 245-247.
Brzozowski A., Dmoszyńska A. Bone marrow-derived Endothelial Progenitor Cells: the biology, functions and
clinical applications. Acta Haematol Pol 2004; 35 (2): 177-187.
Janic B, Arbab AS. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal 2010; 10: 1088-1099.
Lin EH., Jiang Y., Deng Y., et al. Cancer stem cells, endothelial progenitors, and mesenchymal stem cells: “seed and soil” theory revisited, Gastrointest Cancer Res 2008; 2 (4): 169-174.
Sun XT., Yuan XW., Zhu HT., et al. Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma. World J Gastroenterol 2012; 18 (35): 4925-4933.
Wojtukiewicz MZ., Sierko E. The approach to antiangiogenic therapy in cancer patients. Onkol Prak Klin 2009; 5: 1-14.
Banyś A., Bułaś L., Długosz E., et al. Angiogeneza w chorobie nowotworowej. Farm Pol 2009; 65 (4): 247-250.
Medinger M., Mross K. Clinical trials with antiangiogenic agents in hematological malignancies, J Angiogenes Res 2010; 2: 1-11.
Mizia - Malarz A., Sobol G., Woś H. Angiogenesis in the chronic inflammatory diseases and malignancies. Pol Merk Lek 2008; 25 (141): 185-189.
Jurczyszyn A., Wolska-Smoleń T., Skotnicki AB. Angiogenesis in normal and neoplastic hematopoesis. Adv Clin Exp Med 2003; 12 (4): 489-496.
Kapielko-Słowiek K., Urbaniak-Kujda D., Wołowiec D., et al. Serum concentration of angiogenin in patients with acute lymphoblastic leukemia and acute myeloid leukemia and its relationship with clinical course of the disease. Acta Haematol Pol 2008; 39 (1): 63-71.
Rafat N., Beck GCh., Schulte J., et al. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 2010; 112 (1): 43-49.
Wideł SM., Wideł M. Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Postepy Hig Med Dosw 2006; 60: 453-470
Beerepoot LV., Mehra N., Vermaat JS., et al. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol; 2004; 15 (1): 139-145.
Oppliger Leibundgut E., Horn MP., Brunold C., et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Hematologica 2006; 91 (11): 1465-1472.
Alonci A., Allegra A., Bellomo G., et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008; 26 (4): 235-239.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 459
Number of citations: 0
